Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01330901
Other study ID # TOPAS
Secondary ID
Status Completed
Phase Phase 2
First received April 5, 2011
Last updated June 3, 2013
Start date October 2011
Est. completion date May 2013

Study information

Verified date June 2013
Source Charite University, Berlin, Germany
Contact n/a
Is FDA regulated No
Health authority Germany: Paul-Ehrlich-Institut
Study type Interventional

Clinical Trial Summary

This study is aimed at investigation of efficacy and safety of ustekinumab (monoclonal antibody against interleukin 12 and 23) treatment in patients with active ankylosing spondylitis (AS) fulfilling the modified New York criteria who have had an inadequate response to standard therapy with non-steroidal anti-inflammatory drugs (NSAIDs) or do not tolerate or have a contraindication for NSAIDs.


Description:

This study is a prospective, open-label, proof-of-concept clinical trial that will be conducted in a referral center for patients with AS in Berlin. Eligible patients will be treated with ustekinumab 90 mg given subcutaneously at weeks 0, 4, and 16. The entire study period accounts 28 weeks. Assessment of the primary outcome parameter will be performed at week 24. The patients will be closely monitored throughout the study on a total of 9 visits.


Recruitment information / eligibility

Status Completed
Enrollment 22
Est. completion date May 2013
Est. primary completion date April 2013
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Age of =18 years.

2. Definite diagnosis of AS according to the modified New York criteria.

3. History of an inadequate response to =2 NSAIDs taken for at least 2 weeks each or NSAIDs intolerance/contraindication.

4. Active disease as defined by a BASDAI value of =4 at screening despite concomitant treatment with an NSAID or without NSAIDs in case of intolerance/contraindication.

5. Able and willing to give a written informed consent and comply with the requirements of the study protocol.

6. If female: either not of child-bearing potential (menopausal since 1 year or surgically sterile) or is willing and able to practice a reliable method of contraception.

7. If male: either not of child-bearing potential (surgically sterilized, e.g. vasectomy) or is willing and able to practice a reliable method of contraception.

8. If on NSAIDs: the dose must be stable for at least 2 weeks prior to baseline.

9. If on oral steroids: the dose must not exceed 10 mg (prednisolone equivalent) per day and must be stable for at least 4 weeks prior to baseline.

10. If on methotrexate: the dose must not exceed 25 mg per week and must be stable for at least 4 weeks prior to baseline, must be stable for 4 weeks prior to baseline.

11. If on analgesics: the dose must be stable for at least 2 weeks prior to baseline.

Exclusion Criteria:

1. The female subject is pregnant or lactating.

2. Patients with other chronic inflammatory articular disease or systemic autoimmune disease.

3. History of inadequate response to previous anti-tumor necrosis factor (TNF) a therapy.

4. Previous treatment with biologics other than TNF a blockers.

5. Treatment with any other investigational drug within 4 weeks of 5 half-life of the drug (whichever is longer) prior to baseline.

6. Treatments with disease modifying anti-rheumatic drugs (DMARDs) other than methotrexate within 4 weeks prior to screening (8 weeks for leflunomide or 4 weeks with a standard cholestyramine wash-out).

7. Treatment with intravenous, intramuscular or intraarticular/periarticular steroids within 4 weeks prior to screening.

8. Any active current infection, a history of recurrent clinically significant infection, infections requiring treatment with antibiotics within 4 weeks prior to baseline.

9. Current clinical signs and symptoms suggestive for tuberculosis.

10. Positive interferon gamma release assay (IGRA) test at screening and/or abnormal chest x-ray (performed at screening or within 3 months prior to screening) suggestive for past or present tuberculosis (positive x-ray). Patients with a positive IGRA test but negative chest x-ray and without clinical symptoms suggestive for tuberculosis may participate in the study after initiation of standard prophylactic antimycobacterial treatment.

11. Chronic infection with hepatitis B or C, history of human immunodeficiency virus infection.

12. Primary or secondary immunodeficiency.

13. Actual malignancies or history of malignancies with curative treatment within 5 years prior to screening, except successfully treated non-metastatic squamous-cell or basal-cell carcinoma or carcinoma in situ of the cervix.

14. Evidence of severe uncontrolled gastrointestinal, hepatic, renal, pulmonary, cardiovascular, nervous or endocrine disorders.

15. Any other conditions making the patient unsuitable in the opinion of the investigator for the participation in the current study.

16. Patients with a history of a severe psychiatric illness, which might interfere with the patient's ability to understand the requirements of the study and assessment.

17. Diagnosis of fibromyalgia.

18. Alcohol abuse or illegal drug consume in the last 12 months.

19. Vaccination with a live vaccine within 12 weeks prior to baseline.

20. Known hypersensitivity to any component of the study medication.

21. Clinically significant laboratory abnormalities

22. Patients who are institutionalised due to regulatory or juridical order.

23. Patients with contraindications for the magnetic resonance imaging (MRI)

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Drug:
Ustekinumab
Ustekinumab 90 mg given subcutaneously at weeks 0, 4, and 16

Locations

Country Name City State
Germany Department of Rheumatology, Charité - Campus Benjamin Franklin Berlin

Sponsors (1)

Lead Sponsor Collaborator
Charite University, Berlin, Germany

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary The Assessment of Spondyloarthritis International Society (ASAS)40 response The percentage of patients who achieved ASAS40 response defined as an improvement of =40% and =2 points in at least 3 out of four following domains (and no worsening in remaining domain):
Patient global
Pain
Function (as measured by the Bath Ankylosing Spondylitis Functional Index - BASFI)
Inflammation (mean of the Bath Ankylosing Spondylitis Disease Activity Index - BASDAI question 5 and 6)
week 24 No
Secondary The Assessment of Spondyloarthritis International Society (ASAS)20 response at week 24 The percentage of patients who achieved ASAS20 response defined as an improvement of =20% and =1 points in at least 3 out of four following domains (and no worsening of =20% and =1 points in remaining domain):
Patient global
Pain
Function (as measured by the Bath Ankylosing Spondylitis Functional Index - BASFI)
Inflammation (mean of the Bath Ankylosing Spondylitis Disease Activity Index - BASDAI question 5 and 6)
Week 24 No
Secondary The Ankylosing Spondylitis Disease Activity Score (ASDAS) clinically important improvement The percentage of patients who achieved the ASDAS clinically important improvement (=1.1) at week 24 Week 24 No
Secondary The Assessment of Spondyloarthritis International Society (ASAS) partial remission The percentage of patients who achieved partial remission according to the ASAS definition at week 24 Week 24 No
Secondary The Ankylosing Spondylitis Disease Activity Score (ASDAS) major improvement The percentage of patients who achieved the ASDAS major improvement (=2.0) at week 24 Week 24 No
Secondary Number of participants with adverse events as a measure of safety and tolerability Number of participants with adverse events as a measure of safety and tolerability up to week 28 Week 28 Yes
See also
  Status Clinical Trial Phase
Terminated NCT02685904 - A Multicentre Study to Evaluate the Efficacy and Safety of ENIA11 in Patients With Ankylosing Spondylitis Phase 3
Completed NCT02186873 - A Study of Golimumab in Participants With Active Ankylosing Spondylitis Phase 3
Completed NCT01668004 - The Incidence of Extra-Articular Manifestations in Participants With Ankylosing Spondylitis Treated With Golimumab (MK-8259-012) Phase 4
Completed NCT05051943 - A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
Completed NCT01934933 - Etanercept and Celecoxib Alone/Combined Treatment in Effectiveness and Safety of Active Ankylosing Spondylitis Phase 4
Not yet recruiting NCT04875299 - Optimal Adalimumab Plasma Concentrations in Ankylosing Spondylitis Patients
Completed NCT02763111 - Clinical Trial to Evaluate Efficacy and Safety of Multiple Subcutaneous Injections of Various Doses of BCD-085 in Patients With Active Ankylosing Spondylitis Phase 2
Completed NCT02758782 - NSAIDs Added to Anti-TNF Therapy Versus Anti-TNF Therapy Alone on Progression of Structural Damage in Ankylosing Spondylitis Phase 4
Active, not recruiting NCT02687620 - Does Immunogenicity Have an Influence on the Efficacy of Anti-TNF Therapy in Patients With AS: An Inception Cohort Study
Completed NCT02154425 - A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers Phase 1
Completed NCT01750528 - Prevalence and Progression of Periodontitis in Ankylosing Spondylitis N/A
Completed NCT01463189 - Web-based Support to Manage Arthritis Pain Phase 2
Completed NCT01091675 - Assessment of the Response to Etoricoxib in Patients With Ankylosing Spondylitis and Inadequate Response to ≥2 NSAIDs Phase 3
Completed NCT00844805 - Infliximab for Treatment of Axial Spondyloarthritis (P05336 AM1) Phase 3
Recruiting NCT00747578 - Health-Related Quality of Life and Disease-Related Costs: Comparison Between Ankylosing Spondylitis, Rheumatoid Arthritis and Systemic Lupus Erythematosus in Taiwan N/A
Completed NCT00715091 - Effects of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) on RAdiographic Damage in Ankylosing Spondylitis Phase 4
Completed NCT01083693 - Quality of Life Outcomes of HUMIRA in Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS) After Unsustainable Response to Biologicals and Disease Modifying Antirheumatic Drugs N/A
Not yet recruiting NCT00517101 - Presence of IBD Specific Antibodies (ASCA, ALCA, ACCA, AMCA) in the Sera of Patients With Spondyloarthropathy N/A
Completed NCT00367211 - Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PN 200 or Naproxen in Subjects Who Are at Risk for Developing NSAID-Associated Ulcers. Phase 3
Completed NCT00133315 - TNFalfa Blocking Treatment of Spondylarthropathies Phase 4